Ischemic preconditioning: from molecular mechanisms to therapeutic opportunities.
about
Ischemic conditioning-induced endogenous brain protection: Applications pre-, per- or post-strokeBerbamine postconditioning protects the heart from ischemia/reperfusion injury through modulation of autophagyCytoplasmic signaling in the control of mitochondrial uproar?Ischaemic preconditioning-regulated miR-21 protects heart against ischaemia/reperfusion injury via anti-apoptosis through its target PDCD4.Endometriosis, a modern syndrome.The surmountable effect of FSCPX, an irreversible A(1) adenosine receptor antagonist, on the negative inotropic action of A(1) adenosine receptor full agonists in isolated guinea pig left atria.RETRACTED: Microarray analysis for differentially expressed genes of patients undergoing total knee arthroplasty with ischemia preconditioning.Toll-like receptors in ischaemia and its potential role in the pathophysiology of muscle damage in critical limb ischaemia.The mitochondrial death pathway: a promising therapeutic target in diseasesLoss of the miR-144/451 cluster impairs ischaemic preconditioning-mediated cardioprotection by targeting Rac-1.Unexpected pro-injury effect of propofol on vascular smooth muscle cells with increased oxidative stressBlockade of electron transport before ischemia protects mitochondria and decreases myocardial injury during reperfusion in aged rat heartsA novel RNA-binding protein, Ossa/C9orf10, regulates activity of Src kinases to protect cells from oxidative stress-induced apoptosis.Long-term insulin treatment restores cardioprotection induced by sufentanil postconditioning in diabetic rat heart.Mentation on the immunological modulation of gastrointestinal motility.Mitochondrial superoxide production and respiratory activity: biphasic response to ischemic duration.Astragaloside IV enhances cardioprotection of remote ischemic conditioning after acute myocardial infarction in rats.Nox1 NADPH oxidase is necessary for late but not early myocardial ischaemic preconditioning.Ischemic preconditioning: Interruption of various disorders.Mitochondrial reprogramming through cardiac oxygen sensors in ischaemic heart disease.The molecular basis of recurrent pregnancy loss: impaired natural embryo selection.NADPH oxidases as a source of oxidative stress and molecular target in ischemia/reperfusion injury.Genetics and genomics of ischemic tolerance: focus on cardiac and cerebral ischemic preconditioning.Site-specific antioxidative therapy for prevention of atherosclerosis and cardiovascular disease.Identification of activators of methionine sulfoxide reductases A and B.The endometrium from the neonate to the adolescent.Piezo channels and GsMTx4: Two milestones in our understanding of excitatory mechanosensitive channels and their role in pathology.The Protective Role of the TOPK/PBK Pathway in Myocardial Ischemia/Reperfusion and H₂O₂-Induced Injury in H9C2 Cardiomyocytes.Diazoxide protects L6 skeletal myoblasts from H2O2-induced apoptosis via the phosphatidylinositol-3 kinase/Akt pathway.The Slo(w) path to identifying the mitochondrial channels responsible for ischemic protection.Partial adenosine A1 receptor agonists for cardiovascular therapies.GsMTx4-D is a cardioprotectant against myocardial infarction during ischemia and reperfusion.Hypoxic Air Inhalation and Ischemia Interventions Both Elicit Preconditioning Which Attenuate Subsequent Cellular Stress In vivo Following Blood Flow Occlusion and Reperfusion.Myocardial ischemic reperfusion induces de novo Nrf2 protein translation.Remote ischemic preconditioning protects human neural stem cells from oxidative stress.Diazoxide pretreatment enhances L6 skeletal myoblast survival and inhibits apoptosis induced by hydrogen peroxide.Novel role of NADPH oxidase in ischemic myocardium: a study with Nox2 knockout mice.
P2860
Q28082979-C8D39D74-6DE3-4309-9CC3-5E78AE53972DQ30844779-EE349E0D-031E-4D43-B068-073530818E08Q33361448-1DFC347B-C133-4AAF-A277-9AC79C239429Q33997657-B2C35898-1C5B-482B-9F37-E202D98D2616Q34197366-47EF3833-7067-410D-9A6A-2F3111394937Q34330752-B0FBE9B6-9C36-446A-81F2-39C5DBF18C79Q34981538-9EEE52F0-7BD7-49EA-ACA6-BDD4F32A59CCQ35791682-7155043E-6D70-48AA-BA51-ADF2639FE2BDQ35831981-36BA2A9C-5498-45CA-9D2E-A5C322DD4B01Q35902471-9739BB55-8166-4758-8564-6735D665B35CQ35923104-FF915F72-4429-4CCA-B545-6088D6447022Q36176962-7A4C944F-F5AB-4C4E-AE1C-544B36A81046Q37033630-A00EBF8E-8527-4327-932E-82C3C8784D9EQ37107072-4F29A2CC-BA00-4622-A2FF-A84952E05364Q37134553-35CD03A3-E709-4BEE-AD5D-4BDC635D2E52Q37204423-A584CD53-3B15-4FC6-A767-841B6527D15EQ37448086-F15E79BF-8588-44E0-AB56-622A48C73FC1Q37644770-18D05FA1-94AD-4460-8B44-9CD244B0F924Q37721389-CC60BB97-7A2A-4228-B157-883E630089C1Q37777273-774E83A4-3FF2-483A-BE8A-D63C0F0D6F86Q37789541-A9929CE2-06F6-42B3-B262-F6700011EAADQ38054458-6A722E3D-2599-4467-B8C1-8DA42E3C6195Q38061499-225AE9DB-7557-4D15-A694-A5CE6A1F3520Q38112118-11EE32F3-241A-4406-843D-B26B7D40FA38Q38440194-28D2D7D0-16E3-43EF-BF60-360D3D86B473Q38469838-D7B6A3E7-AC99-41BD-847A-8F3713BE7370Q38646692-2799140D-D244-4111-A3C4-3918BDBA7951Q38791620-DEA5E59A-E26D-4B93-B03F-B3E0E1CA63FFQ38822862-97315C4D-49BA-4586-A381-36DE6F8C6E2EQ39363477-E7696DA6-5502-4F47-B1F7-7365637BD691Q40643364-646A6F2F-EEDB-4BF4-9B47-9E41C29A2D3BQ41112302-0F611962-79A0-4BDF-8C1D-5EBF3D5B52BFQ41203178-A6D02E03-6D25-4BA8-B4F7-160A079E0861Q42236573-B4936278-BA19-4277-A716-41CDA8D6A8F5Q47738316-AA534A3A-20D0-4BAA-A561-3838B64F3997Q53190888-838A123C-1616-4BEC-BF42-C9C85626CA06Q54341815-3B495ED4-2A97-4AE7-9073-607D3195E45A
P2860
Ischemic preconditioning: from molecular mechanisms to therapeutic opportunities.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Ischemic preconditioning: from molecular mechanisms to therapeutic opportunities.
@en
type
label
Ischemic preconditioning: from molecular mechanisms to therapeutic opportunities.
@en
prefLabel
Ischemic preconditioning: from molecular mechanisms to therapeutic opportunities.
@en
P356
P1476
Ischemic preconditioning: from molecular mechanisms to therapeutic opportunities.
@en
P2093
Hajime Otani
P304
P356
10.1089/ARS.2007.1679
P577
2008-02-01T00:00:00Z